A phase 1 dose escalation study of lapatinib and paclitaxel in recurrent ovarian cancer

被引：0
|
作者：
Cao, Connie D.
McCorkle, Joseph R.
Yan, Donglin
Jayswal, Rani
Miller, Rachel W.
Dietrich, Charles S.
Ueland, Frederick R.
Kolesar, Jill M.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 05期
关键词：
D O I：
10.1158/1538-7445.OVARIAN23-B021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B021
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I/II dose-escalation and expansion study of afuresertib plus carboplatin and paclitaxel in recurrent ovarian cancer.
    Blagden, Sarah Patricia
    Gabra, Hani
    Hamilton, Anne L.
    Wong, Shirley S.
    Michael, Agnieszka
    Mileshkin, Linda R.
    Hall, Marcia
    Goh, Jeffrey
    Lisyanskaya, Alla Sergeevua
    DeSilvio, Michelle
    Habr, Dany
    Gainer, Shelby
    Gopalakrishna, Prashanth
    Meniawy, Tarek
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] A phase I, dose escalation study of lapatinib in combination with carboplatin, paclitaxel, with and without trastuzumab in patients with metastatic breast cancer
    Storniolo, A. M.
    Rubin, P.
    Magrinat, G.
    Parker, B.
    Rush-Tayler, A.
    Sheidler, V
    Aranjo, S.
    Shaw, C.
    Eldreth, N.
    Lott, G.
    Brechlin, J.
    Loftiss, J., I
    Fleming, R. A.
    Weber, B. L.
    CANCER RESEARCH, 2009, 69 (02) : 238S - 238S
  • [3] Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
    Blagden, Sarah P.
    Hamilton, Anne L.
    Mileshkin, Linda
    Wong, Shirley
    Michael, Agnieszka
    Hall, Marcia
    Goh, Jeffrey C.
    Lisyanskaya, Alla S.
    DeSilvio, Michelle
    Frangou, Eleni
    Stronach, Euan A.
    Gopalakrishna, Prashanth
    Meniawy, Tarek M.
    Gabra, Hani
    CLINICAL CANCER RESEARCH, 2019, 25 (05) : 1472 - 1478
  • [4] A Phase I, Dose Escalation Study of Lapatinib in Combination with Carboplatin, Paclitaxel, with or without Trastuzumab in Patients with Metastatic Breast Cancer: An Update.
    Storniolo, A. M.
    Magrinat, G.
    Rubin, P.
    Parker, B.
    Rush-Taylor, A.
    Sheidler, V
    Aranjo, S.
    Shaw, C.
    Eldreth, N.
    Lott, G.
    Brechlin, J.
    Loftiss, J.
    Arya, N.
    Fleming, R. A.
    CANCER RESEARCH, 2009, 69 (24) : 678S - 679S
  • [5] A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer
    Cadoo, Karen A.
    Grisham, Rachel N.
    O'Cearbhaill, Roisin E.
    Boucicaut, Nicole N.
    Henson, Melissa
    Iasonos, Alexia
    Zhou, Qin
    Sarasohn, Debra M.
    Gallagher, Jacqueline
    Kravetz, Sara
    Zamarin, Dmitriy
    Makker, Vicky
    Sabbatini, Paul J.
    Tew, William P.
    Aghajanian, Carol
    Konner, Jason A.
    GYNECOLOGIC ONCOLOGY, 2020, 157 (01) : 214 - 221
  • [6] A phase 1b dose escalation study of ipafricept (OMP-54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer
    Moore, Kathleen N.
    Gunderson, Camille C.
    Sabbatini, Paul
    McMeekin, D. Scott
    Mantia-Smaldone, Gina
    Burger, Robert A.
    Morgan, Mark A.
    Kapoun, Ann M.
    Brachmann, Rainer Karl
    Stagg, Robert
    Farooki, Azeez
    O'Cearbhaill, Roisin E.
    GYNECOLOGIC ONCOLOGY, 2019, 154 (02) : 294 - 301
  • [7] A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel
    Gordon, AN
    Hancock, KC
    Matthews, CM
    Stringer, A
    Boston, J
    Nemunaitis, J
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (06): : 601 - 605
  • [8] A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer
    Adachi, S
    Ogasawara, T
    Ito, K
    Koyama, M
    Nagano, T
    Suzuki, A
    Yamada, T
    Nakata, Y
    Ozawa, M
    ONCOLOGY REPORTS, 2001, 8 (02) : 285 - 288
  • [9] A phase I dose escalation study of a 2 day lapatinib chemosensitization pulse preceding weekly intravenous nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in patients with advanced cancer
    Chien, A. J.
    Illi, J. A.
    Ko, A. H.
    Dubey, S.
    Jahan, T. M.
    Hylton, N. M.
    Yeh, B. M.
    Huang, Y.
    Koch, K. M.
    Moasser, M. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer
    Kyi, Chrisann
    Doubrovina, Ekaterina
    Zhou, Qin
    Kravetz, Sara
    Iasonos, Alexia
    Aghajanian, Carol
    Sabbatini, Paul
    Spriggs, David
    O'Reilly, Richard J.
    O'Cearbhaill, Roisin E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)
12345